Evaluación de la presencia de inmunidad humoral específica contra SARS-COV-2 causante del COVID-19 en mujeres de la UPS sede Quito en edades comprendidas entre 18 a 23 años, posterior al proceso de vacunación

Abstract

COVID-19 is a pandemic caused by the SARS-CoV-2 virus responsible for the development of severe respiratory syndromes and that currently there are some vaccines that have managed to mitigate the impact of the virus; However, little is known about the effects of immunity generation after the application of vaccines, therefore, within the framework of epidemiological surveillance in Ecuador, the Ministry of Public Health with authorization MSP-SNVSP-2022-0082-O authorized the determination of the presence of specific humoral immunity against SARS-CoV-2 causing COVID-19 in women from UPS Quito headquarters aged 18 to 23 years, after the vaccination process, For this purpose, immunoassay tests (BIOMERICA) were performed for the qualitative detection of IgG and IgM antibodies against SARS-CoV-2 in capillary blood samples. The results showed that the study population exceeded the recommended sample by approximately 3 times, being 19 years of age the most frequent age in this study with 3 doses of vaccine administered and with a high frequency of not having acquired COVID-19 either before or after vaccination. In addition, the highest frequency of immunization was performed with the Sinovac vaccine in women with two doses and AstraZeneca with three doses; however, the sample analyzed reported that despite having three doses administered, the frequency of not having immunity (350) was higher than that of having immunity (300). Finally, the relationship between the presence of immunity and the type of vaccines administered showed that the combination of Sinovac and AstraZeneca vaccine obtained a higher percentage of not having prolonged humoral immunity, a percentage similar to that obtained in previous research.